Oncologix Tech Stock Beta
OCLG Stock | USD 0.0001 0.00 0.00% |
Oncologix Tech fundamentals help investors to digest information that contributes to Oncologix Tech's financial success or failures. It also enables traders to predict the movement of Oncologix Pink Sheet. The fundamental analysis module provides a way to measure Oncologix Tech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncologix Tech pink sheet.
Oncologix |
Oncologix Tech Company Beta Analysis
Oncologix Tech's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Oncologix Tech Beta | 1.27 |
Most of Oncologix Tech's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncologix Tech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Competition |
In accordance with the recently published financial statements, Oncologix Tech has a Beta of 1.2713. This is 55.04% higher than that of the Health Care Providers & Services sector and significantly higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Oncologix Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncologix Tech's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Oncologix Tech could also be used in its relative valuation, which is a method of valuing Oncologix Tech by comparing valuation metrics of similar companies.Oncologix Tech is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Oncologix Tech will likely underperform.
Oncologix Fundamentals
Return On Asset | -0.12 | |||
Profit Margin | (0.38) % | |||
Operating Margin | (0.13) % | |||
Current Valuation | 3.18 M | |||
Shares Outstanding | 340.13 M | |||
Price To Earning | (0.03) X | |||
Price To Sales | 0.17 X | |||
Revenue | 2.85 M | |||
Gross Profit | 614.41 K | |||
EBITDA | (572.25 K) | |||
Net Income | (2.37 M) | |||
Cash And Equivalents | 86.31 K | |||
Total Debt | 3.97 M | |||
Current Ratio | 0.28 X | |||
Book Value Per Share | (0) X | |||
Cash Flow From Operations | (24.2 K) | |||
Earnings Per Share | (0.01) X | |||
Number Of Employees | 191 | |||
Beta | 1.27 | |||
Market Capitalization | 612.23 K | |||
Total Asset | 1.5 M | |||
Retained Earnings | (49.86 M) | |||
Working Capital | (3.35 M) | |||
Current Asset | 1.31 M | |||
Current Liabilities | 4.67 M | |||
Z Score | -47.6 | |||
Net Asset | 1.5 M |
About Oncologix Tech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncologix Tech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncologix Tech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncologix Tech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Oncologix Pink Sheet
Oncologix Tech financial ratios help investors to determine whether Oncologix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncologix with respect to the benefits of owning Oncologix Tech security.